The legislative instrument and the following digest, which constitutes no part of
the legislative instrument, were prepared by Christopher D. Adams.
CONFERENCE COMMI TTEE REPORT DIGEST
Senate Bill No. 496 by Senator Heitmeier
Keyword and summary of the bill as proposed by the Conference Committee
CONTROL DANGER SUBSTANCE. Provides for limits on certain prescriptions. (8/1/14)
Report adopts House amendments to:
1. Make a technical correction.
Report rejects House amendments which would have:
1. Added that the pharmacist licensed in a state contiguous to Louisiana to those
who can prescribe.
2. Clarified that medication is a narcotic Schedule II controlled dangerous substance.
3. Reduced from 90 to 30 days the time within which a pharmacist is not to again
dispense the narcotic Schedule II.
Report amends the bill to:
1. Clarify the restriction for dispensing is for an opiod derivative Schedule II or an
opiod derivative Schedule III.
2 Reduce from 90 days to 60 days the time within which a pharmacist is not to
again dispense the opiod derivative Schedule II or the opiod derivative Schedule
III.
Digest of the bill as proposed by the Conference Committee
Present law provides no prescription for a Schedule II substance may be refilled.
Proposed law provides a Schedule II prescription may not be filled more than 90 days after the date of the prescription.
Proposed law provides a pharmacist not dispense more than a ten-day supply at a dosage not to
exceed the United States Food and Drug Administration's approved labeling for the medication if
the prescriber is not licensed by the state of Louisiana, and the medication is an opiod derivative
Schedule II or an opiod derivative Schedule III controlled dangerous substance. Furthermore, the
dispensing pharmacist shall notify the prescriber of the supply dispensed and the cancellation of
the remainder of the prescription.
Proposed law provides within 60 days of the dispensing of a medication pursuant to proposed
law, such medication shall not be dispensed again for the individual by a prescriber not licensed
by the state of Louisiana.
Proposed law provides a prescriber shall access the Prescription Monitoring Program prior to
initially prescribing any Schedule II controlled dangerous substance to a patient for the treatment
of non-cancer-related chronic or intractable pain.
Effective August 1, 2014.